

Studies on RA Derivatives. V. Synthesis and Antitumor Activity of Ala²-Modified RA-VII Derivatives¹⁾

Hideji ITOKAWA,* Kazuyuki KONDO, Yukio HITOTSUYANAGI, Megumi ISOMURA, and Koichi TAKEYA

Tokyo College of Pharmacy, Horinouchi 1432-1, Hachioji, Tokyo 192-03, Japan. Received January 18, 1993

A number of RA-VII derivatives having various amino acids including proline (6), pipercolic acid (11), norvaline (12), ornithine (14), aspartic acid (15) and methionine (20) in place of Ala² have been synthesized from RA-X methyl ester (3) and evaluated for cytotoxicity to P388 leukemia and KB cells *in vitro*. Comparison of the cytotoxicity of these compounds suggests that the polarity and the length of the 2nd amino acid residue affect the activity. An NMR study revealed that, in solution, 6 and 11 are locked in one conformational state, corresponding to conformer A of RA-VII.

Keywords RA-VII; cyclic hexapeptide; antitumor activity; cytotoxicity; RA-X methyl ester; conformationally locked derivative

RA-VII (1) is a bicyclic hexapeptide isolated from the roots of *Rubia akane* and *R. cordifolia* (Rubiaceae).²⁾ It has attracted much attention because of its significant antileukemic and antitumor activities coupled with its characteristic structure incorporating the isodityrosine moiety. Recently RA-VII-related compounds which have serine (RA-III, 2),²⁾ threonine (RA-VIII),³⁾ pyroglutamic acid (RA-IX) or glutamic acid (RA-X)⁴⁾ in place of alanine at the 2nd position have been isolated from the same plants. The cytotoxicity of these compounds is estimated to range from 0.0023 to 0.37 $\mu\text{g}/\text{ml}$ against P388 leukemia cells. These large differences in the activity are presumably due to the changes in the structure at the 2nd position. In order to obtain information about the structural effect of the 2nd amino acid (Aa²) side chain on the cytotoxic activity, we planned to prepare a number of Aa²-modified RA derivatives which have not been isolated from natural sources.

This paper describes the preparation of Ala²-modified RA-VII derivatives, some aspects of their conformations in solution, and the evaluation of their antitumor activity.

Chemistry The starting material was RA-X methyl ester (3).⁴⁾ The manipulation of the ester group of 3 afforded proline (6), pipercolic acid (11), norvaline (12), ornithine (14), aspartic acid (15), homoserine (17), vinyl glycine (19) and methionine (20) derivatives. The synthetic scheme for these derivatives is depicted in Charts 1 and 2.

RA-X methyl ester (3) was reduced with lithium borohydride (LiBH₄) in tetrahydrofuran (THF) at room temperature to provide the alcohol 4 in 74% yield. The alcohol 4 was treated with methanesulfonyl chloride (MsCl) and triethylamine (Et₃N) at -78 °C in dichloromethane (CH₂Cl₂) in the presence of 4-dimethylaminopyridine (DMAP) to afford the mesylate 5 in 96% yield. Compound 5 was then cyclized in CH₂Cl₂-50% NaOH containing 0.5 eq of tetra-*n*-butylammonium bromide (*n*-Bu₄NBr) to provide the proline derivative 6 in 82% yield.

Preparation of the pipercolic acid derivative 11 required C₁ elongation, which was conducted by means of the following procedures. The mesylate 5 was reacted with *o*-nitrophenyl selenocyanate (*o*-NO₂PhSeCN) and sodium borohydride (NaBH₄)⁵⁾ in EtOH, and hydrogen peroxide oxidation of the resultant aryl selenide provided the allylglycine derivative 7 in 94% yield. Compound 7 was

subjected to Lemieux-Jonson oxidation with osmium tetroxide (OsO₄) and sodium periodate (NaIO₄) in dioxane-H₂O to provide the aldehyde 8 in 76% yield. Condensation of 8 with ethyl diethylphosphonoacetate and sodium hydride (NaH) in the presence of 18-crown-6 in THF gave α,β -unsaturated ester 9 (72%), which was subjected to catalytic hydrogenation, and successive reduction of the ester group with LiBH₄ provided the alcohol 10 in 31% yield. The alcohol 10 was converted to the pipercolic acid derivative 11 *via* the mesylate in a manner similar to that described for 6 in 56% yield from 10.

Catalytic hydrogenation of 7 afforded the norvaline derivative 12 in 87% yield. The ornithine derivative 14 was obtained by triphenylphosphine (Ph₃P) reduction of the azide intermediate 13, which was prepared from the mesylate 5.

Aspartic acid (15), vinylglycine (19) and methionine (20) derivatives were prepared from the aldehyde 8. Direct oxidation of the aldehyde 8 with silver(II) oxide (AgO) in THF-H₂O afforded the aspartic acid derivative 15 in poor yield (14%). However, more satisfactory results were obtained by a two-step procedure involving hemiacetal oxidation followed by saponification of the resultant ester. Thus, the aldehyde 8 was reacted with *N*-iodosuccinimide (NIS) in methanol (MeOH)⁶⁾ to afford the methyl ester 16, which was successively treated with lithium hydroxide (LiOH) in MeOH-H₂O to provide 15 in 59% yield from 8.

The aldehyde 8 was reduced with NaBH₄ in 1,4-dioxane, and the resulting alcohol 17 (90%) was mesylated to afford 18 in 71% yield. The vinylglycine derivative 19 was prepared from 18 in the same manner as described for 7 in 17% yield. Substitution reaction of 18 with sodium thiomethoxide (NaSCH₃) in chloroform (CHCl₃) or THF gave the oxazine 21 as a major product with a small amount of the desired methionine derivative 20. However, after conversion of 18 into the corresponding iodide, treatment with NaSCH₃ in MeOH provided 20 in 91% yield.

All stereogenic centers of the obtained derivatives remained intact through the reactions, as indicated by comparisons of their chemical shifts and/or coupling constants in the proton (¹H) and carbon 13 (¹³C) nuclear magnetic resonance (NMR) spectra with those of RA-VII (Table I).

Conformational Information Naturally occurring RAs




Chart 1. Structure and Synthetic Scheme of RA Derivatives

Ala=L-alanine, Tyr=*N,O*-dimethyl-L-tyrosine, D-Ala=D-alanine, Aa=L-amino acid. a) LiBH₄, THF, r.t., 12 h. b) MsCl, DMAP, Et₃N, CH₂Cl₂, -78 °C, 1 h. c) *n*-Bu₄Br, CH₂Cl₂-50% NaOH, r.t., 1 h. d) *o*-NO₂PhSeCN, NaBH₄, EtOH, r.t., 3 h; H₂O₂, THF-EtOH, r.t., 12 h; (CH₃)₂S, r.t., 12 h. e) OsO₄, NaIO₄, 1,4-dioxane-H₂O, r.t., 18 h. f) Ethyl diethylphosphonoacetate, NaH, 18-crown-6, THF, r.t., 12 h. g) H₂, 10% Pd-C, 1,4-dioxane, r.t., 24 h; LiBH₄, THF, r.t., 24 h. h) NaN₃, 18-crown-6, CH₂Cl₂, reflux, 9 h. i) H₂, 10% Pd-C, 1,4-dioxane, r.t., 24 h. j) Ph₃P, H₂O, THF, r.t., 62 h.

adopt two or three conformational states in solution.¹H- and ¹³C-NMR spectroscopy, including two-dimensional (2D) NMR and molecular dynamics calculation studies for RA-VII revealed the two conformers, A and B, observed in CDCl₃ solution to be the *trans* and *cis* amide isomers with respect to the peptide bond between Ala² and Tyr³, respectively.⁷⁾ The conformer ratio of natural RAs is influenced by structure, solvent and temperature, and the conformer A predominates (*ca.* 80–100%) in all cases. Similar conformational tendencies were observed in the derivatives prepared in this study. Among them, the proline (**6**) and pipercolic acid (**11**) derivatives showed a single conformer in various solvent(s), which suggested that these compounds are conformationally locked in one rigid structure (Table II). To elucidate the solution conformation of **6**, conformational analysis was performed.

All proton and carbon resonances of **6** were unambiguously assigned by ¹H-¹H correlated spectroscopy (H-H COSY),⁸⁾ heteronuclear multiple quantum coherence (HMQC)⁹⁾ and heteronuclear multiple bond connectivity (HMBC)⁶⁾ spectra. The ¹H- and ¹³C-NMR parameters of **6** are quite similar to those of the major conformer of RA-VII. Phase-sensitive nuclear Overhauser effect spectroscopy (NOESYPH)¹⁰⁾ correlations between Pro²-C_αH and Tyr³-NMe; Tyr³-NMe and Tyr³-C_αH also suggest the presence of a *trans* peptide bond between Pro² and Tyr³ (Fig. 1). The temperature coefficients ($\Delta\delta/\Delta T$) of the Ala⁴-NH shifts in dimethyl sulfoxide (DMSO)-*d*₆¹¹⁾ indicate internal hydrogen bonding to D-Ala¹ carbonyl oxygen, which can stabilize the backbone conformation (Table III).

Circular dichroism (CD) curve of **6** shows positive Cotton






Chart 2

a) NIS, K₂CO₃, CH₃OH, r.t., 7 h. b) LiOH, CH₃OH:H₂O=2:1, r.t., 4 h. c) AgO, THF:H₂O=9:1, reflux, 9 h. d) NaBH₄, 1,4-dioxane, r.t., 3 h. e) MsCl, DMAP, Et₃N, CH₂Cl₂, -78 °C, 2 h. f) *o*-NO₂PhSeCN, NaBH₄, EtOH, r.t., 24 h; H₂O₂, THF-EtOH, r.t., 12 h; (CH₃)₂S, r.t., 2 h. g) NaI, CH₃COCH₂CH₃, reflux, 10 h; NaSCH₃, CH₃OH, r.t., 0.5 h.

Fig. 1. Selected NOE Correlations of 6 in DMSO-*d*₆ at 303 K

effects at 287 and 215 nm, and negative ones at 233 and 206 nm. The strong band indicates rigid backbone geometry (Fig. 2).

Biological Results and Discussion Thirteen RA derivatives including intermediates prepared in this study were evaluated for *in vitro* cytotoxicity against P388 leukemia

Fig. 2. The CD Spectrum of 6 in CH₃OH

and KB cells, and RA-VII (1) and III (2) were re-evaluated for comparison (Table IV).

Compounds which possess a polar functionality at the side chain showed reduced activity, especially in the case

TABLE I. ^{13}C -NMR Spectral Data for RA Derivatives

| Amino acid carbon | | 4 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 ^{a)} | 16 | 17 | 19 | 20 | |
|--------------------|------------------|------------------------------|----------------------------|--------|--------|--------|--------|--------|--------|--------|--------|------------------|--------|--------|--------|--------|--------|
| D-Ala ¹ | C _α | 47.93 | 46.93 | 47.96 | 46.18 | 47.59 | 48.00 | 46.23 | 47.90 | 48.06 | 47.81 | 46.31 | 46.23 | 46.93 | 47.94 | 47.79 | |
| | C _β | 20.70 | 18.17 | 20.87 | 21.05 | 20.94 | 20.84 | 18.18 | 20.84 | 20.94 | 20.89 | 20.79 | 20.81 | 20.82 | 20.70 | 20.85 | |
| Aa ² | C _α | 48.94 | 55.51 | 48.20 | 47.95 | 47.94 | 49.06 | 47.84 | 48.67 | 48.41 | 49.25 | 47.79 | 47.92 | 48.09 | 51.88 | 47.82 | |
| | C _β | 27.76 | 25.26 | 35.50 | 45.87 | 32.79 | 30.96 | 17.97 | 33.33 | 25.02 | 23.68 | 35.25 | 35.93 | 33.47 | 131.52 | 30.40 | |
| | C _γ | 28.26 | 28.16 | 132.06 | 197.96 | 142.40 | 22.04 | 24.46 | 18.84 | 28.48 | 27.35 | | 52.08 | 58.70 | 120.16 | 30.05 | |
| | C _δ | 61.94 | 46.78 | 119.58 | | 125.49 | 32.11 | 25.11 | 13.80 | 50.84 | 39.36 | | | | | | 15.36 |
| | C _ε | | | | | 60.60 | 62.17 | 42.75 | | | | | | | | | |
| | C _ζ | | | | | 14.22 | | | | | | | | | | | |
| Tyr ³ | C _α | 68.41 | 68.28 | 68.69 | 69.21 | 68.84 | 68.51 | 67.96 | 68.56 | 68.52 | 68.62 | 68.92 | 68.95 | 68.58 | 68.57 | 68.38 | |
| | C _β | 32.99 | 32.96 | 32.92 | 32.75 | 32.79 | 32.97 | 32.89 | 32.92 | 32.92 | 32.96 | 32.63 | 32.82 | 32.97 | 32.75 | 32.84 | |
| | C _γ | 130.67 | 131.03 | 130.86 | 130.93 | 130.70 | 130.78 | 130.21 | 130.81 | 130.61 | 130.98 | 130.47 | 131.03 | 130.78 | 130.61 | 130.57 | |
| | C _δ | 130.14 | 130.20 | 130.29 | 130.29 | 130.12 | 130.25 | 130.21 | 130.21 | 130.19 | 130.25 | 130.22 | 130.27 | 130.13 | 130.32 | 130.09 | |
| | C _ε | 114.12 | 114.03 | 114.05 | 114.06 | 114.18 | 114.08 | 114.02 | 114.00 | 114.11 | 114.31 | 114.10 | 114.06 | 114.09 | 114.04 | 114.00 | |
| | C _ζ | 158.43 | 158.30 | 158.42 | 158.36 | 158.45 | 158.43 | 158.38 | 158.39 | 158.27 | 158.25 | 158.32 | 158.29 | 158.44 | 158.43 | 158.09 | |
| | C _N | 39.95 | 39.91 | 39.84 | 40.25 | 33.93 | 39.91 | 39.46 | 39.81 | 39.88 | 40.16 | 40.21 | 40.09 | 39.86 | 39.68 | 39.98 | |
| | C _O | 55.25 | 55.24 | 55.28 | 55.26 | 55.23 | 55.29 | 55.23 | 55.23 | 55.28 | 55.23 | 55.23 | 55.23 | 55.29 | 55.25 | 55.20 | |
| | Ala ⁴ | C _α | 46.36 | 46.27 | 46.37 | 43.97 | 46.30 | 46.39 | 45.58 | 46.32 | 46.39 | 46.23 | 45.52 | 45.37 | 46.47 | 46.51 | 46.22 |
| | | C _β | 18.54 | 18.15 | 18.60 | 16.80 | 18.60 | 18.60 | 17.97 | 18.50 | 18.58 | 18.67 | 18.44 | 18.67 | 18.51 | 18.41 | 18.51 |
| | Tyr ⁵ | C _α | 54.28 | 54.86 | 54.22 | 55.26 | 54.19 | 54.22 | 54.69 | 54.19 | 54.13 | 54.59 | 54.26 | 54.31 | 54.11 | 54.21 | 54.15 |
| C _β | | 36.98 | 36.82 | 37.04 | 37.00 | 37.02 | 37.03 | 36.87 | 36.97 | 37.05 | 36.99 | 36.90 | 36.99 | 36.97 | 36.99 | 36.91 | |
| C _γ | | 135.08 | 135.72 | 135.11 | 135.06 | 135.05 | 135.09 | 135.52 | 135.09 | 135.03 | 135.33 | 134.92 | 135.12 | 134.99 | 135.10 | 135.06 | |
| C _{δα} | | 132.77 | 132.66 | 132.79 | 132.73 | 132.77 | 132.78 | 132.69 | 132.75 | 132.81 | 132.69 | 132.72 | 132.72 | 132.91 | 132.81 | 132.67 | |
| C _{δb} | | 130.93 | 130.87 | 131.00 | 130.97 | 130.96 | 131.00 | 130.93 | 130.96 | 131.01 | 130.98 | 130.93 | 130.94 | 130.91 | 130.96 | 130.95 | |
| C _{εa} | | 124.22 | 124.04 | 124.27 | 124.27 | 124.28 | 124.29 | 124.06 | 124.21 | 124.31 | 124.20 | 124.22 | 124.23 | 124.32 | 124.26 | 124.15 | |
| C _{εb} | | 125.88 | 125.91 | 125.92 | 125.95 | 125.91 | 125.93 | 125.89 | 125.89 | 125.93 | 125.95 | 125.94 | 125.91 | 125.90 | 125.91 | 125.85 | |
| C _ζ | | 158.24 | 158.18 | 158.26 | 158.23 | 158.25 | 158.27 | 158.17 | 158.23 | 158.50 | 158.56 | 158.17 | 158.37 | 158.31 | 158.24 | 158.31 | |
| C _N | | 30.51 | 30.66 | 30.50 | 30.47 | 30.47 | 30.52 | 30.52 | 30.46 | 30.50 | 30.58 | 30.48 | 30.42 | 30.56 | 30.53 | 30.45 | |
| C _O | | 57.41 | 56.98 | 57.44 | 57.45 | 57.45 | 57.45 | 57.11 | 57.41 | 57.47 | 57.37 | 57.37 | 57.49 | 57.45 | 57.41 | 57.30 | |
| Tyr ⁶ | C _β | 35.44 | 35.75 | 35.40 | 35.29 | 35.33 | 35.40 | 35.72 | 35.38 | 35.35 | 35.46 | 35.60 | 35.36 | 35.30 | 35.46 | 35.31 | |
| | C _γ | 128.18 | 128.31 | 128.15 | 128.05 | 128.09 | 128.15 | 128.29 | 128.19 | 128.10 | 128.34 | 128.01 | 128.23 | 128.10 | 128.17 | 128.02 | |
| | C _{δα} | 120.67 | 121.16 | 120.91 | 120.90 | 120.90 | 120.92 | 121.04 | 120.89 | 120.89 | 121.06 | 120.90 | 120.90 | 120.94 | 120.92 | 120.84 | |
| | C _{δb} | 113.45 | 113.34 | 113.44 | 113.38 | 113.41 | 113.43 | 113.37 | 113.44 | 113.42 | 113.32 | 113.32 | 113.54 | 113.43 | 113.43 | 113.28 | |
| | C _{εa} | 112.40 | 112.32 | 112.35 | 112.31 | 112.33 | 112.35 | 112.35 | 112.38 | 112.32 | 112.41 | 112.21 | 112.55 | 112.35 | 112.34 | 112.18 | |
| | C _{εb} | 153.15 | 153.12 | 153.15 | 153.10 | 153.12 | 153.15 | 153.12 | 153.13 | 153.14 | 153.13 | 152.98 | 153.22 | 153.14 | 153.12 | 152.98 | |
| | C _ζ | 146.52 | 146.57 | 146.55 | 146.51 | 146.52 | 146.55 | 146.55 | 146.51 | 146.54 | 146.55 | 146.42 | 146.58 | 146.55 | 146.52 | 146.38 | |
| | C _N | 29.28 | 29.61 | 29.24 | 29.21 | 29.20 | 29.26 | 29.51 | 29.21 | 28.48 | 29.37 | 29.27 | 29.19 | 29.23 | 29.28 | 29.18 | |
| | C _O | 56.17 | 56.15 | 56.19 | 56.15 | 56.16 | 56.18 | 56.15 | 56.17 | 56.18 | 56.20 | 56.09 | 56.23 | 56.13 | 56.18 | 56.07 | |
| | C _{C=O} | 168.02 | 168.59 (Tyr ³) | 167.80 | 167.73 | 165.63 | 167.90 | 168.52 | 167.69 | 167.71 | 168.03 | 167.94 | 167.78 | 167.87 | 167.87 | 167.87 | 167.82 |
| 169.36 | | 168.67 (Tyr ⁵) | 169.42 | 169.50 | 167.57 | 169.43 | 168.78 | 169.40 | 169.48 | 169.16 | 169.40 | 169.47 | 169.46 | 169.37 | 169.31 | | |
| 170.68 | | 170.08 (D-Ala ¹) | 170.62 | 170.70 | 169.45 | 170.65 | 170.69 | 170.60 | 170.54 | 170.56 | 170.78 | 170.28 | 170.50 | 170.42 | 170.53 | | |
| 171.75 | | 170.94 (Tyr ⁶) | 171.36 | 170.78 | 170.56 | 171.77 | 171.67 | 171.73 | 171.62 | 171.43 | 171.21 | 170.68 | 171.83 | 170.62 | 171.40 | | |
| 172.11 | | 171.71 (Ala ⁴) | 171.77 | 171.61 | 170.78 | 172.08 | 171.78 | 172.14 | 171.76 | 172.17 | 171.44 | 170.75 | 171.89 | 171.79 | 171.57 | | |
| 172.33 | | 172.01 (Pro ²) | 172.07 | 171.97 | 171.67 | 172.28 | 172.81 | 172.24 | 172.51 | 172.93 | 172.12 | 171.67 | 172.55 | 172.19 | 172.31 | | |

In CDCl₃, major conformer, 100 MHz, δ -values. a) 75 MHz.

TABLE II. Conformer Ratio (A:B) of RA Derivatives

| Compound | CDCl ₃ | | DMSO- <i>d</i> ₆ | | CD ₃ OD | |
|----------------------|-------------------|------|-----------------------------|-----|--------------------|-----|
| | A | B | A | B | A | B |
| RA-VII ⁶⁾ | 89 | : 11 | | | | |
| 6 | 100 | : 0 | 100 | : 0 | 100 | : 0 |
| 11 | 100 | : 0 | | | | |

TABLE III. Effect of Temperature on the NH Chemical Shift of **6** in DMSO-*d*₆

| $\Delta\delta/\Delta T$ (ppm/K) | D-Ala ¹ | Ala ⁴ |
|---------------------------------|--------------------|-----------------------|
| | | 4.66×10^{-3} |

of ornithine (**14**) and aspartic acid (**15**) derivatives. In this connection, it is noteworthy that ϵ -hydroxynorleucine (**10**) and homoserine (**17**) derivatives are less toxic than

TABLE IV. Cytotoxicity of RA Derivatives toward P388 Leukemia and KB Cells

| Compound | IC ₅₀ ($\mu\text{g/ml}$) | |
|-------------------|---------------------------------------|--------|
| | P388 | KB |
| 1 (RA-VII) | 0.0013 | 0.0023 |
| 2 (RA-III) | 0.011 | 0.024 |
| 4 | 0.14 | 0.084 |
| 6 | 0.079 | 0.074 |
| 7 | 0.031 | 0.059 |
| 8 | 0.027 | 0.031 |
| 10 | 0.18 | 0.14 |
| 11 | 0.079 | 0.21 |
| 12 | 0.011 | 0.019 |
| 13 | 0.030 | 0.013 |
| 14 | > 10 | > 10 |
| 15 | 0.99 | 1.88 |
| 17 | 0.048 | 0.052 |
| 19 | 0.020 | 0.042 |
| 20 | 0.017 | 0.040 |

TABLE V. *In Vivo* Antitumor Activity of RA Derivatives toward P388 Leukemia

| Compound | T/C (%) Dose (mg/kg) | | | | | |
|-------------------|----------------------|-----|------|-------|------|------|
| | 0.4 | 1.6 | 3.13 | 6.25 | 12.5 | 25.0 |
| 1 (RA-VII) | 144 | 152 | 163 | Toxic | | |
| 2 (RA-III) | 149 | 156 | | 160 | 159 | |
| 6 | 101 | 107 | | 121 | 128 | 132 |
| 15 | 96 | 103 | | 126 | | |
| 20 | 116 | 146 | | 158 | | |

P388 cells (10^6) were transplanted intraperitoneally (i.p.) into CDF₁ mice on day 0 and the compound were administered i.p. on days 1–5. T/C (%) = (mean survival time of tested mice)/(mean survival time of control mice) × 100.

methionine (**20**) and norvaline (**12**) derivatives, respectively, having a non-polar residue with similar length.

Another clear relationship exists between the length of the residue and cytotoxicity. In a series of compounds having a hydroxyl group at the end of the side chain, cytotoxicity decreases with increase in the length of the carbon chain (**2** > **17** > **4** > **10**). The same tendencies are observed among other homologues (e.g. **19** > **7** > **1** > **12**). However, the observation that the azido intermediate **13** having a rather long residue shows high cytotoxicity suggests that a lengthy side chain can be compatible with activity in the case of a less polar functionality.

The conformationally locked derivatives, **6** and **11**, show potent cytotoxicity, suggesting that this conformation is an active one for expressing the activity.

The proline (**6**), aspartic acid (**15**) and methionine (**20**) derivatives were evaluated for *in vivo* antitumor activity against P388 leukemia (Table V). The observed antitumor activities of these compounds approximately paralleled the cytotoxicities.

Experimental

Melting points were determined on a Yanagimoto micromelting point apparatus and were not corrected. Infrared (IR) spectra were taken on a Perkin Elmer 1710 spectrophotometer. Optical rotations were measured with a JASCO DIP-360 polarimeter, and $[\alpha]_D$ values are given in 10^{-1} deg cm² g⁻¹. The ¹H- and ¹³C-NMR spectra were recorded on Bruker AM-400, AM-500 and Varian Gemini 300 spectrometers. Chemical shifts were expressed in ppm with tetramethylsilane as an internal standard. The mass spectra (MS) were taken with Hitachi M-80 and VG AutoSpecE spectrometers. The ultraviolet (UV) and visible absorption spectra were recorded on a Shimadzu UV-240 spectrometer. CD spectra were recorded on a JASCO J-702 spectrometer. Silicagel column chromatography was performed with a CIG column system (22 mm i.d. × 100 mm, Kusano Scientific Co., Tokyo) prepacked with 10 μ silica gel.

[2-(δ-Hydroxynorvaline)]-RA-VII (4) A solution of LiBH₄ in THF (2 M, 2.0 ml, 4.0 mmol) was added to a solution of **3** (842.4 mg, 1.0 mmol) in THF (30 ml). The mixture was stirred at room temperature for 12 h, then concentrated *in vacuo*, and the residue was dissolved in CH₂Cl₂. This solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1), followed by recrystallization from MeOH-isopropyl ether to give **4** (603 mg, 74%) as a colorless powder, mp 231–232°C, $[\alpha]_D -93.3^\circ$ ($c=0.15$, CHCl₃). IR ν (CHCl₃): 3404, 1673, 1636 cm⁻¹. UV λ_{max} (EtOH) nm (log ε): 220 (4.48), 278 (3.63), 283 (3.59). High-resolution FAB-MS Calcd for C₄₃H₅₅N₆O₉: 815.3980 [M+H]⁺, Found: 815.3915. FAB-MS *m/z* (%): 815 (10, [M+1]⁺), 121 (100). ¹H-NMR (CDCl₃, major conformer, δ): 1.10 (3H, d, $J=6.7$ Hz, Ala⁴-H_β), 1.30 (3H, d, $J=6.8$ Hz, Ala¹-H_β), 1.55–1.61 (2H, m, Nva²-H_β), 1.79–1.88 (2H, m, Nva²-H_γ), 2.63 (1H, dd, $J=11.4$, 3.0 Hz, Tyr⁵-H_{βa}), 2.68 (3H, s, Tyr⁶-NMe), 2.93 (3H, s, Tyr³-NMe), 2.99 (1H, dd, $J=18.3$, 4.2 Hz, Tyr⁶-H_{βa}), 3.09 (1H, dd, $J=18.3$, 12.1 Hz, Tyr⁶-H_{βb}), 3.11 (3H, s, Tyr⁵-NMe), 3.27 (1H, dd, $J=14.5$,

11.3 Hz, Tyr³-H_{βa}), 3.40 (1H, dd, $J=14.5$, 4.0 Hz, Tyr³-H_{βb}), 3.61 (1H, dd, $J=11.3$, 4.0 Hz, Tyr³-H_γ), 3.63–3.69 (3H, m, Nva²-H_γ), 3.78 (3H, s, Tyr³-OMe), 3.92 (3H, s, Tyr⁶-OMe), 4.34 (1H, d, $J=1.8$ Hz, Tyr⁶-H_{βa}), 4.41 (1H, dq, $J=7.1$, 6.8 Hz, Ala¹-H_γ), 4.55 (1H, dd, $J=12.0$, 4.2 Hz, Tyr⁶-H_γ), 4.71–4.76 (2H, m, Ala¹-H_γ and Nva²-H_γ), 5.40 (1H, dd, $J=11.4$, 3.0 Hz, Tyr⁵-H_γ), 6.54 (1H, d, $J=7.1$ Hz, Ala¹-NH), 6.57 (1H, dd, $J=8.4$, 1.8 Hz, Tyr⁶-H_{βb}), 6.57 (1H, dd, $J=8.4$, 1.8 Hz, Tyr⁶-H_{βb}), 6.74 (1H, d, $J=7.6$ Hz, Ala²-NH), 6.79 (1H, d, $J=8.4$ Hz, Tyr⁶-H_γ), 6.82 (2H, d, $J=8.6$ Hz, Tyr³-H_γ), 6.87 (1H, dd, $J=8.4$, 2.4 Hz, Tyr⁵-H_{βa}), 7.05 (2H, d, $J=8.6$ Hz, Tyr⁶-H_β), 7.19 (1H, dd, $J=8.4$, 2.4 Hz, Tyr⁵-H_{βb}), 7.25 (1H, dd, $J=8.4$, 2.2 Hz, Tyr⁵-H_{βa}), 7.40 (1H, dd, $J=8.4$, 2.2 Hz, Tyr⁵-H_{βb}).

[2-(δ-Hydroxynorvaline)]-RA-VII Mesylate (5) MsCl (0.43 ml, 5.6 mmol) was added dropwise to a stirred solution of **4** (760 mg, 0.93 mmol), DMAP (340 mg, 2.79 mmol) and Et₃N (0.38 ml, 2.8 mmol) in CH₂Cl₂ (50 ml) at -78°C. The mixture was stirred at -78°C for 1 h, diluted with CH₂Cl₂, washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1) to give **5** (797 mg, 96%) as an amorphous powder. ¹H-NMR (CDCl₃, major conformer, δ): 1.10 (3H, d, $J=7.5$ Hz, Ala⁴-H_β), 1.30 (3H, d, $J=6.9$ Hz, Ala¹-H_β), 1.50–1.90 (4H, m, Nva²-H_β and Nva²-H_γ), 2.63 (1H, dd, $J=11.2$, 3.1 Hz, Ala¹-H_{βa}), 2.67 (3H, s, Tyr⁶-NMe), 2.92 (3H, s, Tyr³-NMe), 2.92–3.09 (2H, m, Tyr⁶-H_β), 3.02 (3H, s, Nva²-OMs), 3.13 (3H, s, Tyr⁵-NMe), 3.31 (1H, dd, $J=14.6$, 11.1 Hz, Tyr³-H_{βa}), 3.41 (1H, dd, $J=14.6$, 4.6 Hz, Tyr³-H_{βb}), 3.63 (1H, dd, $J=11.1$, 4.6 Hz, Tyr³-H_γ), 3.66 (1H, t, $J=11.2$ Hz, Tyr⁵-H_{βb}), 3.78 (3H, s, Tyr³-OMe), 3.93 (3H, s, Tyr⁶-OMe), 4.25 (2H, t, $J=5.9$ Hz, Nva²-H_γ), 4.34 (1H, d, $J=2.1$ Hz, Tyr⁶-H_{βa}), 4.39 (1H, dq, $J=8.9$, 6.9 Hz, Ala¹-H_γ), 4.53 (1H, dd, $J=12.0$, 4.0 Hz, Tyr⁶-H_γ), 4.72 (1H, qd, $J=7.5$, 7.2 Hz, Ala⁴-H_γ), 4.79–4.84 (1H, m, Nva²-H_γ), 5.38 (1H, dd, $J=11.2$, 3.1 Hz, Tyr⁵-H_γ), 6.37 (1H, d, $J=6.9$ Hz, Nva²-NH), 6.57 (1H, dd, $J=8.4$, 2.1 Hz, Tyr⁶-H_{βb}), 6.60 (1H, d, $J=8.9$ Hz, Ala¹-NH), 6.70 (1H, d, $J=7.2$ Hz, Ala⁴-NH), 6.80 (1H, d, $J=8.4$ Hz, Tyr⁶-H_γ), 6.84 (2H, d, $J=8.6$ Hz, Tyr³-H_γ), 6.87 (1H, dd, $J=8.4$, 2.4 Hz, Tyr⁵-H_{βa}), 7.05 (2H, d, $J=8.6$ Hz, Tyr³-H_β), 7.20 (1H, dd, $J=8.4$, 2.4 Hz, Tyr⁵-H_{βb}), 7.26 (1H, dd, $J=8.4$, 2.2 Hz, Tyr⁵-H_{βa}), 7.41 (1H, dd, $J=8.4$, 2.2 Hz, Tyr⁵-H_{βb}).

[2-Proline]-RA-VII (6) A mixture of **5** (35.8 mg, 0.040 mmol), *n*-Bu₄NBr (6.5 mg, 0.020 mmol), CH₂Cl₂ (4 ml) and 50% NaOH (1 ml) was stirred vigorously at room temperature for 1 h. The mixture was diluted with CH₂Cl₂, washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1), followed by recrystallization from MeOH-isopropyl ether to give **6** (26.1 mg, 82%) as a colorless powder, mp 294–295°C, $[\alpha]_D -148.1^\circ$ ($c=0.11$, CHCl₃). IR ν (CHCl₃): 3400, 1680, 1651 cm⁻¹. UV λ_{max} (EtOH) nm (log ε): 225 (4.52), 277 (3.63), 283 (3.56). High-resolution FAB-MS Calcd for C₄₃H₅₃N₆O₉: 797.3910 [M+H]⁺. Found: 797.3873. FAB-MS *m/z* (%): 797 (20, [M+H]⁺). ¹H-NMR (CDCl₃, δ): 0.95 (3H, d, $J=6.7$ Hz, Ala⁴-H_β), 1.26 (3H, d, $J=6.7$ Hz, Ala¹-H_β), 1.95–2.05 (3H, m, Pro²-H_{βa} and Pro²-H_γ), 2.59–2.63 (2H, m, Pro²-H_{βb} and Tyr⁵-H_{βa} (pro-R)), 2.78 (3H, s, Tyr⁶-NMe), 2.85 (1H, dd, $J=17.9$, 3.7 Hz, Tyr⁶-H_{βa} (pro-S)), 3.06 (3H, s, Tyr⁵-NMe), 3.17 (1H, dd, $J=17.9$, 12.0 Hz, Tyr⁶-H_{βb} (pro-R)), 3.25 (1H, dd, $J=14.1$, 10.9 Hz, Tyr³-H_{βa}), 3.38 (1H, dd, $J=14.1$, 4.5 Hz, Tyr³-H_{βb}), 3.50 (1H, dt, $J=9.7$, 7.3 Hz, Pro²-H_{βa}), 3.58 (1H, dd, $J=10.9$, 4.5 Hz, Tyr³-H_γ), 3.63 (1H, dd, $J=9.7$, 4.4 Hz, Pro²-H_{βb}), 3.71 (1H, t, $J=11.1$ Hz, Tyr⁵-H_{βb} (pro-S)), 3.78 (3H, s, Tyr³-OMe), 3.92 (3H, s, Tyr⁶-OMe), 4.32 (1H, d, $J=1.8$ Hz, Tyr⁶-H_{βa}), 4.50 (1H, dq, $J=13.5$, 6.7 Hz, Ala¹-H_γ), 4.55 (1H, dd, $J=12.0$, 3.7 Hz, Tyr⁶-H_γ), 4.72 (1H, dd, $J=7.8$, 2.9 Hz, Pro²-H_γ), 4.89 (1H, td, $J=15.5$, 6.7 Hz, Ala⁴-H_γ), 5.49 (1H, dd, $J=11.1$, 2.5 Hz, Tyr⁵-H_γ), 6.56 (1H, dd, $J=8.3$, 1.8 Hz, Tyr⁶-H_{βb}), 6.79 (1H, d, $J=8.3$ Hz, Tyr⁶-H_γ), 6.82–6.86 (2H, m, Ala¹-NH, Ala⁴-NH), 6.83 (2H, d, $J=8.5$ Hz, Tyr³-H_γ), 6.85 (1H, dd, $J=8.4$, 2.4 Hz, Tyr⁵-H_{βa}), 7.05 (2H, d, $J=8.5$ Hz, Tyr³-H_β), 7.19 (1H, dd, $J=8.4$, 2.4 Hz, Tyr⁵-H_{βb}), 7.25 (1H, dd, $J=8.4$, 2.1 Hz, Tyr⁵-H_{βb}), 7.40 (1H, dd, $J=8.4$, 2.1 Hz, Tyr⁵-H_{βb}).

[2-Allylglycine]-RA-VII (7) A mixture of **5** (89.3 mg, 0.10 mmol), *o*-NO₂PhSeCN (90.8 mg, 0.40 mmol), NaBH₄ (18.2 mg, 0.48 mmol) and EtOH (10 ml) was stirred at room temperature for 3 h. The mixture was concentrated *in vacuo*, and the residue was dissolved in CH₂Cl₂. This solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1) to give the selenide. 35% H₂O₂ (2 ml) was added to the selenide dissolved in THF-EtOH (1:1, 20 ml), and the mixture was stirred

at room temperature for 12 h. Dimethyl sulfide was added to the mixture at room temperature to decompose excess H₂O₂. The whole was stirred for 12 h, and concentrated *in vacuo*. The residue was dissolved in CH₂Cl₂. This solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1), followed by recrystallization from MeOH-isopropyl ether to give **7** (75.1 mg, 94%) as a colorless powder, mp 227–228 °C, [α]_D²⁰ -199.4° (*c*=0.10, CHCl₃). IR ν (CHCl₃): 3413, 1674, 1636 cm⁻¹. UV λ_{\max} (EtOH) nm (log ϵ): 220 (4.60), 227 (3.78), 283 (3.71). High-resolution FAB-MS Calcd for C₄₃H₅₃N₆O₉: 797.3874 [M+H]⁺. Found: 797.3918. MS *m/z* (%): 796 (20, M⁺), 121 (100). ¹H-NMR (CDCl₃, major conformer, δ): 1.13 (3H, d, *J*=6.7 Hz, Ala⁴-H _{β}), 1.29 (3H, d, *J*=6.9 Hz, Ala¹-H _{β}), 2.42–2.54 (2H, m, Aa²-H _{β}), 2.63 (1H, dd, *J*=11.3, 2.9 Hz, Tyr⁵-H _{β}), 2.68 (3H, s, Tyr⁶-NMe), 2.92 (3H, s, Tyr³-NMe), 3.13 (3H, s, Tyr⁵-NMe), 3.29 (1H, dd, *J*=14.2, 11.1 Hz, Tyr³-H _{β}), 3.45 (1H, dd, *J*=14.2, 4.2 Hz, Tyr³-H _{β}), 3.60 (1H, dd, *J*=11.1, 4.2 Hz, Tyr³-H _{β}), 3.67 (1H, t, *J*=11.3 Hz, Tyr⁵-H _{β}), 3.79 (3H, s, Tyr³-OMe), 3.94 (3H, s, Tyr⁶-OMe), 4.34 (1H, d, *J*=2.1 Hz, Tyr⁶-H _{α}), 4.37 (1H, t, *J*=6.9 Hz, Ala¹-H _{α}), 4.54 (1H, dd, *J*=12.0, 3.9 Hz, Tyr⁶-H _{α}), 4.74 (1H, dq, *J*=7.5, 6.7 Hz, Ala⁴-H _{α}), 4.84 (1H, m, Aa²-H _{β}), 5.18 (1H, dd, *J*=10.3, 1.4 Hz, Aa²-H _{α}), 5.22 (1H, dd, *J*=17.1, 1.4 Hz, Aa²-H _{β}), 5.40 (1H, dd, *J*=11.4, 3.2 Hz, Tyr⁵-H _{α}), 5.67–5.77 (1H, m, Aa²-H _{α}), 6.16 (1H, d, *J*=8.7 Hz, Aa²-NH), 6.38 (1H, d, *J*=6.9 Hz, Ala¹-NH), 6.58 (1H, dd, *J*=8.3, 2.1 Hz, Tyr⁶-H _{β}), 6.69 (1H, d, *J*=7.5 Hz, Ala⁴-NH), 6.80 (1H, d, *J*=8.3 Hz, Tyr⁶-H _{α}), 6.83 (2H, d, *J*=8.6 Hz, Tyr³-H _{α}), 6.87 (1H, dd, *J*=8.4, 2.4 Hz, Tyr⁵-H _{α}), 7.08 (2H, d, *J*=8.6 Hz, Tyr³-H _{β}), 7.21 (1H, dd, *J*=8.4, 2.4 Hz, Tyr⁵-H _{β}), 7.26 (1H, dd, *J*=8.4, 2.2 Hz, Tyr⁵-H _{α}), 7.41 (1H, dd, *J*=8.4, 2.4 Hz, Tyr⁵-H _{β}).

[2-(β -Formylalanine)]-RA-VII (8) OsO₄ (20.0 mg, 0.080 mmol) and NaIO₄ (160.4 mg, 0.75 mmol) were added to a solution of **7** (119.5 mg, 0.15 mmol) in 1,4-dioxane-H₂O (4:1, 10 ml) and the mixture was stirred at room temperature for 18 h. The white precipitate was removed by filtration, then the filtrate was diluted with CH₂Cl₂, washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1), followed by recrystallization from MeOH-isopropyl ether to give **8** (91.8 mg, 76%) as a colorless powder, mp 322–323 °C, [α]_D²⁰ -129.8° (*c*=0.13, CHCl₃). IR ν (CHCl₃): 3405, 1725, 1673, 1634 cm⁻¹. UV λ_{\max} (EtOH) nm (log ϵ): 224 (4.44), 277 (3.64), 283 (3.58). High-resolution FAB-MS Calcd for C₄₂H₅₁N₆O₁₀: 799.3667 [M+H]⁺. Found: 799.3722. MS *m/z* (%): 798 (100, M⁺). ¹H-NMR (CDCl₃, major conformer, δ): 1.12 (3H, d, *J*=6.7 Hz, Ala⁴-H _{β}), 1.28 (3H, d, *J*=7.0 Hz, Ala¹-H _{β}), 2.63 (1H, dd, *J*=11.4, 3.2 Hz, Tyr⁵-H _{β}), 2.66 (3H, s, Tyr⁶-NMe), 2.83 (1H, dd, *J*=18.5, 5.0 Hz, Aa²-H _{β}), 2.92–2.95 (1H, m, Tyr⁶-H _{β}), 3.04–3.10 (1H, m, Tyr⁶-H _{β}), 3.12 (3H, s, Tyr³-NMe), 3.15 (1H, dd, *J*=14.2, 10.3 Hz, Tyr³-H _{β}), 3.17 (3H, s, Tyr⁵-NMe), 3.23 (1H, dd, *J*=18.5, 9.2 Hz, Aa²-H _{β}), 3.42 (1H, dd, *J*=14.2, 3.9 Hz, Tyr³-H _{β}), 3.58 (1H, dd, *J*=10.3, 3.9 Hz, Tyr³-H _{β}), 3.66 (1H, t, *J*=11.4 Hz, Tyr⁵-H _{β}), 3.79 (3H, s, Tyr³-OMe), 3.93 (3H, s, Tyr⁶-OMe), 4.34 (1H, d, *J*=1.8 Hz, Tyr⁶-H _{α}), 4.36 (1H, dq, *J*=7.1, 7.0 Hz, Ala¹-H _{α}), 4.56 (1H, dd, *J*=11.9, 3.8 Hz, Tyr⁶-H _{α}), 4.70 (1H, dq, *J*=7.3, 6.7 Hz, Ala⁴-H _{α}), 5.24 (1H, ddd, *J*=9.2, 8.6, 5.9 Hz, Aa²-H _{α}), 5.38 (1H, dd, *J*=11.4, 3.2 Hz, Tyr⁵-H _{α}), 6.40 (1H, d, *J*=7.1 Hz, Ala¹-NH), 6.58 (1H, dd, *J*=8.4, 1.8 Hz, Tyr⁶-H _{β}), 6.77 (1H, d, *J*=7.3 Hz, Ala⁴-NH), 6.80 (1H, d, *J*=8.4 Hz, Tyr⁶-H _{α}), 6.87 (2H, d, *J*=8.6 Hz, Tyr³-H _{α}), 6.87 (1H, dd, *J*=8.4, 2.4 Hz, Tyr⁵-H _{α}), 6.94 (1H, d, *J*=8.6 Hz, Ala²-NH), 7.05 (2H, d, *J*=8.6 Hz, Tyr³-H _{β}), 7.21 (1H, dd, *J*=8.4, 2.4 Hz, Tyr⁵-H _{β}), 7.25 (1H, dd, *J*=8.4, 2.2 Hz, Tyr⁵-H _{α}), 7.40 (1H, dd, *J*=8.4, 2.2 Hz, Tyr⁵-H _{β}), 9.74 (1H, s, Aa²-CHO).

[2-(*E*)-2-Amino-4-hexene-1,6-dicarboxylic acid]-RA-VII Ethyl Ester (9) Ethyl diethylphosphonoacetate (126 μ l, 0.63 mmol), NaH (60%, 25.2 mg, 0.63 mmol) and 18-crown-6 (40.4 mg, 0.15 mmol) were added to a solution of **8** (235.8 mg, 0.29 mmol) in THF (15 ml) at 0 °C. The mixture was stirred at room temperature for 12 h, then concentrated *in vacuo*. The residue was dissolved in CH₂Cl₂. This solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1) to give **9** (185.7 mg, 72%) as an amorphous powder. ¹H-NMR (CDCl₃, major conformer, δ): 1.12 (3H, d, *J*=6.6 Hz, Ala⁴-H _{β}), 1.27 (3H, t, *J*=7.1 Hz, Aa²-COOCH₂CH₃), 1.28 (3H, d, *J*=7.0 Hz, Ala¹-H _{β}), 2.61–2.64 (3H, m, Aa²-H _{β} and Tyr⁶-H _{β}), 2.67 (3H, s, Tyr⁶-NMe), 2.91 (3H, s, Tyr³-NMe), 2.95 (1H, dd, *J*=20.3, 4.1 Hz, Tyr⁶-H _{β}), 3.08 (1H, dd, *J*=20.3, 12.1 Hz, Tyr⁶-H _{β}), 3.13 (3H, s, Tyr⁵-NMe), 3.26 (1H, dd, *J*=14.1, 11.2 Hz,

Tyr³-H _{β}), 3.42 (1H, dd, *J*=14.1, 4.1 Hz, Tyr³-H _{β}), 3.58 (1H, dd, *J*=11.2, 4.1 Hz, Tyr³-H _{α}), 3.66 (1H, t, *J*=11.4 Hz, Tyr⁵-H _{β}), 3.78 (3H, s, Tyr³-OMe), 3.93 (3H, s, Tyr⁶-OMe), 4.20 (2H, q, *J*=7.1 Hz, Aa²-COOCH₂CH₃), 4.33 (1H, d, *J*=1.9 Hz, Tyr⁶-H _{α}), 4.39 (1H, m, Ala¹-H _{α}), 4.54 (1H, dd, *J*=12.1, 4.1 Hz, Tyr⁶-H _{α}), 4.72 (1H, dq, *J*=7.4, 6.6 Hz, Ala⁴-H _{α}), 4.92 (1H, m, Aa²-H _{α}), 5.38 (1H, dd, *J*=11.4, 3.1 Hz, Tyr⁵-H _{α}), 5.97 (1H, d, *J*=15.6 Hz, Aa²-H _{β}), 6.34 (1H, d, *J*=7.0 Hz, Ala¹-NH), 6.50 (1H, d, *J*=9.5 Hz, Aa²-NH), 6.57 (1H, dd, *J*=8.4, 1.8 Hz, Tyr⁶-H _{β}), 6.69 (1H, d, *J*=7.4 Hz, Ala⁴-NH), 6.78–6.89 (1H, m, Aa²-H _{α}), 6.79 (1H, dd, *J*=8.4 Hz, Tyr⁶-H _{α}), 6.83 (2H, d, *J*=8.6 Hz, Tyr³-H _{α}), 6.87 (1H, dd, *J*=8.4, 2.4 Hz, Tyr⁵-H _{α}), 7.03 (2H, d, *J*=8.6 Hz, Tyr³-H _{β}), 7.20 (1H, dd, *J*=8.4, 2.4 Hz, Tyr⁵-H _{β}), 7.26 (1H, dd, *J*=8.4, 2.2 Hz, Tyr⁵-H _{α}), 7.42 (1H, dd, *J*=8.4, 2.2 Hz, Tyr⁵-H _{β}).

[2-(ϵ -Hydroxynorleucine)]-RA-VII (10) Palladium (10%) on activated carbon (100 mg) was added to a solution of **9** (185.7 mg, 0.21 mmol) in 1,4-dioxane (20 ml), and the mixture was stirred vigorously at room temperature for 24 h under hydrogen. The mixture was filtered, and the filtrate was concentrated *in vacuo*. The residue was dissolved in THF (30 ml), and LiBH₄ (2 M in THF, 1.05 ml, 2.3 mmol) was added to the solution at 0 °C. Stirring was continued at room temperature for 24 h, then the mixture was concentrated *in vacuo*. The residue was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1), followed by recrystallization from MeOH-isopropyl ether to give **10** (75.4 mg, 31%) as a colorless powder, mp 227–228 °C, [α]_D²⁰ -176.3° (*c*=0.14, CHCl₃). IR ν (CHCl₃): 3403, 1674, 1636 cm⁻¹. UV λ_{\max} (EtOH) nm (log ϵ): 221 (4.49), 276 (3.62), 282 (3.56). High-resolution FAB-MS Calcd for C₄₄H₅₇N₆O₁₀: 829.4136 [M+H]⁺. Found: 829.4054. FAB-MS *m/z* (%): 829 (10, [M+H]⁺), 121 (100). ¹H-NMR (CDCl₃, major conformer, δ): 1.13 (3H, d, *J*=6.7 Hz, Ala⁴-H _{β}), 1.31 (3H, d, *J*=6.9 Hz, Ala¹-H _{β}), 1.33–1.46 (2H, m, Nle²-H _{β}), 1.54–1.78 (4H, m, Nle²-H _{γ} and Nle²-H _{α}), 2.63 (1H, dd, *J*=11.4, 3.2 Hz, Tyr⁶-H _{β}), 2.68 (3H, s, Tyr⁶-NMe), 2.93 (3H, s, Tyr³-NMe), 2.95 (1H, dd, *J*=18.1, 3.9 Hz, Tyr⁶-H _{β}), 3.10 (1H, dd, *J*=18.1, 12.0 Hz, Tyr⁶-H _{β}), 3.13 (3H, s, Tyr⁵-NMe), 3.31 (1H, dd, *J*=14.2, 11.1 Hz, Tyr³-H _{β}), 3.44 (1H, dd, *J*=14.2, 4.3 Hz, Tyr³-H _{β}), 3.62 (1H, dd, *J*=11.1, 4.3 Hz, Tyr³-H _{α}), 3.64–3.70 (3H, m, Nle²-H _{α} and Tyr⁵-H _{β}), 3.79 (3H, s, Tyr³-OMe), 3.94 (3H, s, Tyr⁶-OMe), 4.34 (1H, d, *J*=1.9 Hz, Tyr⁶-H _{α}), 4.37 (1H, dq, *J*=6.9, 6.8 Hz, Ala¹-H _{α}), 4.54 (1H, dd, *J*=12.0, 3.9 Hz, Tyr⁶-H _{α}), 4.70–4.79 (2H, m, Nle²-H _{α} and Ala⁴-H _{α}), 5.41 (1H, dd, *J*=11.4, 3.2 Hz, Tyr⁵-H _{α}), 6.42 (1H, d, *J*=6.8 Hz, Ala¹-NH), 6.45 (1H, d, *J*=8.6 Hz, Nle²-NH), 6.58 (1H, dd, *J*=8.4, 1.9 Hz, Tyr⁶-H _{β}), 6.72 (1H, d, *J*=7.5 Hz, Ala⁴-NH), 6.80 (1H, d, *J*=8.4 Hz, Tyr⁶-H _{α}), 6.84 (2H, d, *J*=8.6 Hz, Tyr³-H _{α}), 6.88 (1H, dd, *J*=8.4, 2.4 Hz, Tyr⁵-H _{α}), 7.08 (2H, d, *J*=8.6 Hz, Tyr³-H _{β}), 7.21 (1H, dd, *J*=8.4, 2.4 Hz, Tyr⁵-H _{β}), 7.26 (1H, dd, *J*=8.4, 2.2 Hz, Tyr⁵-H _{α}), 7.42 (1H, dd, *J*=8.4, 2.2 Hz, Tyr⁵-H _{β}).

[2-Pipecolic acid]-RA-VII (11) MsCl (42 μ l, 0.54 mmol) was added dropwise to a solution of **10** (75.3 mg, 0.090 mmol), DMAP (33.0 mg, 0.27 mmol) and Et₃N (38 μ l, 0.27 mmol) in CH₂Cl₂ (8 ml) at -78 °C, and stirring was continued for 1 h. The mixture was diluted with CH₂Cl₂, washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1) to afford the mesylate (58.1 mg) as an amorphous powder. A mixture of the mesylate (58.1 mg, 0.064 mmol), *n*-Bu₄NBr (10.3 mg, 0.032 mmol), CH₂Cl₂ (4 ml) and 50% NaOH (1 ml) was stirred vigorously at room temperature for 1 h. The mixture was diluted with CH₂Cl₂, washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1), followed by recrystallization from MeOH-isopropyl ether to give **11** (41.6 mg, 56% from **10**) as a colorless powder, mp 250–251 °C, [α]_D²⁰ -210.2° (*c*=0.11, CHCl₃). IR ν (CHCl₃): 3392, 1681, 1646 cm⁻¹. UV λ_{\max} (EtOH) nm (log ϵ): 220 (4.52), 277 (3.59), 282 (3.54). High-resolution FAB-MS Calcd for C₄₄H₅₅N₆O₉: 811.4031 [M+H]⁺. Found: 811.4089. FAB-MS *m/z* (%): 811 (5, [M+H]⁺). ¹H-NMR (CDCl₃, δ): 0.97 (3H, d, *J*=6.7 Hz, Ala⁴-H _{β}), 1.24 (3H, d, *J*=6.9 Hz, Ala¹-H _{β}), 1.45–1.52 (1H, m, Pip²-H _{α}), 1.63–1.72 (2H, m, Pip²-H _{β}), 1.77–1.81 (1H, m, Pip²-H _{γ}), 1.85–1.88 (1H, m, Pip²-H _{β}), 2.05–2.10 (1H, m, Pip²-H _{β}), 2.60 (1H, dd, *J*=11.2, 2.7 Hz, Tyr⁶-H _{β}), 2.74 (3H, s, Tyr⁶-NMe), 2.83 (3H, s, Tyr³-NMe), 2.89 (1H, dd, *J*=18.0, 3.7 Hz, Tyr⁶-H _{β}), 3.06 (3H, s, Tyr⁵-NMe), 3.13 (1H, dd, *J*=18.0, 12.0 Hz, Tyr⁶-H _{β}), 3.32 (1H, dd, *J*=14.4, 10.3 Hz, Tyr³-H _{β}), 3.35 (1H, dd, *J*=14.4, 5.3 Hz, Tyr³-H _{β}), 3.53 (1H, m, Pip²-H _{α}), 3.53 (1H, dd, *J*=10.3, 5.3 Hz, Tyr³-H _{α}), 3.68 (1H, t, *J*=11.2 Hz, Tyr⁵-H _{β}), 3.92 (1H,

dd, $J = 22.6, 2.3$ Hz, Pip²-H_{bb}), 4.33 (1H, d, $J = 1.8$ Hz, Tyr⁶-H_{aa}), 4.54 (1H, dd, $J = 12.0, 3.7$ Hz, Tyr⁶-H_{ca}), 4.64 (1H, dq, $J = 6.9, 6.7$ Hz, Ala¹-H_z), 4.79 (1H, dq, $J = 8.2, 6.7$ Hz, Ala⁴-H_z), 5.08 (1H, dd, $J = 6.3, 1.8$ Hz, Pip²-H_z), 5.45 (1H, dd, $J = 11.2, 2.7$ Hz, Tyr⁵-H_{ca}), 6.55 (1H, dd, $J = 8.6, 1.8$ Hz, Tyr⁶-H_{bb}), 6.67 (1H, d, $J = 8.2$ Hz, Ala⁴-NH), 6.73 (1H, d, $J = 6.7$ Hz, Ala¹-NH), 6.82 (1H, d, $J = 8.6$ Hz, Tyr⁶-H_z), 6.82 (2H, d, $J = 8.5$ Hz, Tyr³-H_z), 6.86 (1H, dd, $J = 8.4, 2.4$ Hz, Tyr⁵-H_{bb}), 7.04 (2H, d, $J = 8.5$ Hz, Tyr³-H_z), 7.19 (1H, dd, $J = 8.4, 2.4$ Hz, Tyr⁵-H_{bb}), 7.25 (1H, dd, $J = 8.4, 2.1$ Hz, Tyr⁵-H_{aa}), 7.40 (1H, dd, $J = 8.4, 2.1$ Hz, Tyr⁵-H_{bb}).

[2-Norvaline]-RA-VII (12) Palladium (10%) on activated carbon (20 mg) was added to a solution of **7** (39.8 mg, 0.050 mmol) in 1,4-dioxane (5 ml), and the mixture was stirred vigorously at room temperature for 24 h under hydrogen. The mixture was filtered, and the filtrate was concentrated *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1), followed by recrystallization from MeOH to give **12** (34.8 mg, 87%) as a colorless powder, mp 227–228 °C, $[\alpha]_D^{20} -204.5^\circ$ ($c = 0.16$, CHCl₃). IR ν (CHCl₃): 3410, 1674, 1636 cm⁻¹. UV λ_{max} (EtOH) nm (log ϵ): 223 (4.73), 277 (3.85), 282 (3.80). High-resolution FAB-MS Calcd for C₄₃H₅₅N₆O₉: 799.4031 [M+H]⁺. Found: 799.4043. FAB-MS m/z (%): 799 (20, [M+H]⁺), 164 (100), ¹H-NMR (CDCl₃, major conformer, δ): 0.93 (3H, t, $J = 7.3$ Hz, Nva²-H_β), 1.11 (3H, d, $J = 6.7$ Hz, Ala⁴-H_β), 1.28 (3H, d, $J = 6.9$ Hz, Ala¹-H_β), 1.27–1.36 (2H, m, Nva²-H_β), 2.63 (1H, dd, $J = 11.7, 3.1$ Hz, Tyr⁵-H_{βa}), 2.67 (3H, s, Tyr⁶-NMe), 2.91 (3H, s, Tyr³-NMe), 2.96–3.08 (2H, m, Tyr⁶-H_{βa}), 3.11 (3H, s, Tyr⁵-NMe), 3.29 (1H, dd, $J = 14.2, 11.0$ Hz, Tyr³-H_{βa}), 3.43 (1H, dd, $J = 14.2, 4.3$ Hz, Tyr⁵-H_{βb}), 3.61 (1H, dd, $J = 11.0, 4.3$ Hz, Tyr³-H_z), 3.65 (1H, t, $J = 11.7$ Hz, Tyr⁵-H_{βb}), 3.78 (3H, s, Tyr³-OMe), 3.92 (3H, s, Tyr⁶-OMe), 4.34 (1H, d, $J = 2.0$ Hz, Tyr⁶-H_{aa}), 4.37 (1H, t, $J = 6.9$ Hz, Ala¹-H_z), 4.53 (1H, dd, $J = 12.0, 3.9$ Hz, Tyr⁶-H_z), 4.71–4.79 (2H, m, Nva²-H_z and Ala⁴-H_z), 5.39 (1H, dd, $J = 11.7, 3.1$ Hz, Tyr⁵-H_z), 6.42 (1H, d, $J = 6.9$ Hz, Ala¹-NH), 6.56 (1H, d, $J = 8.4$ Hz, Nva²-NH), 6.57 (1H, dd, $J = 8.4, 2.0$ Hz, Tyr⁶-H_{bb}), 6.69 (1H, d, $J = 7.5$ Hz, Ala⁴-NH), 6.79 (1H, d, $J = 8.4$ Hz, Tyr⁶-H_z), 6.82 (2H, d, $J = 8.6$ Hz, Tyr³-H_z), 6.86 (1H, dd, $J = 8.4, 2.4$ Hz, Tyr⁵-H_{aa}), 7.07 (2H, d, $J = 8.6$ Hz, Tyr³-H_z), 7.20 (1H, dd, $J = 8.4, 2.4$ Hz, Tyr⁵-H_{bb}), 7.25 (1H, dd, $J = 8.4, 2.3$ Hz, Tyr⁶-H_{aa}), 7.41 (1H, dd, $J = 8.4, 2.3$ Hz, Tyr⁶-H_{bb}).

[2-(δ-Azidonorvaline)-RA-VII (13)] NaN₃ (588.7 mg, 9.0 mmol), 18-crown-6 (158.6 mg, 0.60 mmol) and **5** (268.9 mg, 0.30 mmol) were dissolved in CH₂Cl₂ (10 ml) and the solution was refluxed for 9 h. The mixture was concentrated *in vacuo*. The residue was dissolved in CH₂Cl₂. This solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1), followed by recrystallization from MeOH-isopropyl ether to give **13** (218.5 mg, 86%) as a colorless powder, mp 211–212 °C, $[\alpha]_D^{20} -209.5^\circ$ ($c = 0.11$, CHCl₃). IR ν (CHCl₃): 3420, 2103, 1677, 1634 cm⁻¹. UV λ_{max} (EtOH) nm (log ϵ): 225 (4.53), 277 (3.66), 285 (3.60). High-resolution FAB-MS Calcd for C₄₃H₅₃N₆O₈: 840.4043 [M+H]⁺. Found: 840.4043. FAB-MS m/z (%): 840 (70, [M+H]⁺), 164 (100), ¹H-NMR (CDCl₃, major conformer, δ): 1.14 (3H, d, $J = 6.6$ Hz, Ala⁴-H_β), 1.31 (3H, d, $J = 6.9$ Hz, Ala¹-H_β), 1.54–1.63 (2H, m, Nva²-H_β), 1.76–1.82 (2H, m, Nva²-H_β), 2.64 (1H, dd, $J = 11.2, 3.0$ Hz, Tyr⁵-H_{βa}), 2.67 (3H, s, Tyr⁶-NMe), 2.91 (3H, s, Tyr³-NMe), 2.96 (1H, dd, $J = 17.7, 3.7$ Hz, Tyr⁶-H_{βa}), 3.10 (1H, dd, $J = 17.7, 11.8$ Hz, Tyr⁶-H_{βb}), 3.14 (3H, s, Tyr⁵-NMe), 3.33 (1H, dd, $J = 14.2, 11.1$ Hz, Tyr³-H_{βa}), 3.33–3.37 (2H, m, Nva²-H_z), 3.44 (1H, dd, $J = 14.2, 4.4$ Hz, Tyr³-H_{βb}), 3.63 (1H, dd, $J = 11.1, 4.4$ Hz, Tyr³-H_z), 3.67 (1H, t, $J = 11.2$ Hz, Tyr⁵-H_{βb}), 3.79 (3H, s, Tyr³-OMe), 3.94 (3H, s, Tyr⁶-OMe), 4.34 (1H, d, $J = 1.8$ Hz, Tyr⁶-H_{aa}), 4.37 (1H, dq, $J = 8.8, 6.6$ Hz, Ala¹-H_z), 4.53 (1H, dd, $J = 11.8, 3.7$ Hz, Tyr⁶-H_z), 4.70 (1H, dq, $J = 7.3, 6.9$ Hz, Ala⁴-H_z), 4.81 (1H, m, Nva²-H_z), 5.39 (1H, dd, $J = 11.2, 3.0$ Hz, Tyr⁵-H_z), 6.24 (1H, d, $J = 8.8$ Hz, Ala¹-NH), 6.35 (1H, d, $J = 6.8$ Hz, Ala²-NH), 6.58 (1H, dd, $J = 8.4, 1.8$ Hz, Tyr⁶-H_{bb}), 6.69 (1H, d, $J = 7.3$ Hz, Ala⁴-NH), 6.80 (1H, d, $J = 8.4$ Hz, Tyr⁶-H_z), 6.84 (2H, d, $J = 8.6$ Hz, Tyr³-H_z), 6.88 (1H, dd, $J = 8.4, 2.4$ Hz, Tyr⁵-H_{aa}), 7.07 (2H, d, $J = 8.6$ Hz, Tyr³-H_z), 7.21 (1H, dd, $J = 8.4, 2.4$ Hz, Tyr⁵-H_{bb}), 7.27 (1H, dd, $J = 8.4, 2.2$ Hz, Tyr⁵-H_{aa}), 7.42 (1H, dd, $J = 8.4, 2.2$ Hz, Tyr⁵-H_{bb}).

[2-Ornithine]-RA-VII (14) A mixture of **13** (153.5 mg, 0.18 mmol), Ph₃P (94.4 mg, 0.36 mmol), H₂O (50 μl) and THF (10 ml) was stirred at room temperature for 62 h. The mixture was concentrated *in vacuo*, and the residue was dissolved in CH₂Cl₂. This solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1), followed by recrystallization from MeOH-isopropyl ether to give **14** (43.8 mg, 29%) as a colorless powder, mp 195–197 °C, $[\alpha]_D^{20} -129.8^\circ$

($c = 0.13$, CHCl₃). IR ν (CHCl₃): 3392, 1662 cm⁻¹. UN λ_{max} (EtOH) nm (log ϵ): 220 (4.35), 277 (3.45), 282 (3.39). High-resolution FAB-MS Calcd for C₄₃H₅₅N₇O₉: 814.4140 [M+H]⁺. Found: 814.4089. FAB-MS m/z (%): 814 (20, [M+H]⁺), ¹H-NMR (CDCl₃, major conformer, δ): 1.06 (3H, d, $J = 6.6$ Hz, Ala⁴-H_β), 1.35 (3H, d, $J = 6.6$ Hz, Ala¹-H_β), 1.77–1.79 (2H, m, Orn²-H_z), 1.97–2.06 (2H, m, Orn²-H_z), 2.19–2.27 (2H, m, Orn²-H_z), 2.61 (1H, dd, $J = 11.2, 2.5$ Hz, Tyr⁵-H_{βa}), 2.68 (3H, s, Tyr⁶-NMe), 2.89–2.94 (1H, m, Tyr⁶-H_{βa}), 2.96 (3H, s, Tyr³-NMe), 3.06–3.10 (1H, m, Tyr⁶-H_{βb}), 3.08 (3H, s, Tyr³-NMe), 3.20 (1H, dd, $J = 13.5, 10.8$ Hz, Tyr³-H_{βa}), 3.34 (1H, dd, $J = 13.5, 4.4$ Hz, Tyr³-H_{βb}), 3.61 (1H, dd, $J = 10.8, 4.4$ Hz, Tyr³-H_z), 3.71 (4H, m, Tyr³-OMe and Tyr⁵-H_{βb}), 3.93 (3H, s, Tyr⁶-OMe), 4.35 (1H, d, $J = 1.4$ Hz, Tyr⁶-H_{aa}), 4.49–4.56 (2H, m, Ala¹-H_z and Tyr⁶-H_z), 4.61 (1H, m, Orn²-H_z), 4.73 (1H, dq, $J = 8.5, 6.6$ Hz, Ala⁴-H_z), 5.42 (1H, dd, $J = 11.2, 2.5$ Hz, Tyr⁵-H_z), 6.43 (1H, d, $J = 6.9$ Hz, Ala¹-NH), 6.57 (1H, dd, $J = 8.2, 1.4$ Hz, Tyr⁶-H_{bb}), 6.79 (1H, d, $J = 8.2$ Hz, Tyr⁶-H_z), 6.81 (2H, d, $J = 8.3$ Hz, Tyr³-H_z), 6.86 (1H, d, $J = 8.5$ Hz, Ala⁴-NH), 6.87 (1H, dd, $J = 8.4, 2.3$ Hz, Tyr⁵-H_{aa}), 7.09 (2H, d, $J = 8.3$ Hz, Tyr³-H_z), 7.20 (1H, dd, $J = 8.5, 2.3$ Hz, Tyr⁵-H_{bb}), 7.25 (1H, dd, $J = 8.4, 2.0$ Hz, Tyr⁵-H_{aa}), 7.40 (1H, dd, $J = 8.5, 2.0$ Hz, Tyr⁵-H_{bb}), 8.76 (1H, d, $J = 6.2$ Hz, Orn²-NH).

[2-Aspartic Acid]-RA-VII (15). a) Oxidation of 8 with AgO AgO (24.8 mg, 0.20 mmol) was added to a solution of **8** (39.9 mg, 0.50 mmol) in THF-H₂O (9:1, 2 ml) and the mixture was refluxed for 9 h. The mixture filtered, and the filtrate was concentrated *in vacuo*. The residue was dissolved in CH₂Cl₂. This solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1), followed by recrystallization from MeOH-isopropyl ether to give **15** (5.7 mg, 14%) as a colorless powder, mp 245–246 °C, $[\alpha]_D^{20} -187.0^\circ$ ($c = 0.11$, CHCl₃). IR ν (CHCl₃): 3395, 1673, 1636 cm⁻¹. UV λ_{max} (EtOH) nm (log ϵ): 220 (4.48), 277 (3.58), 282 (3.52). High-resolution FAB-MS Calcd for C₄₂H₅₅N₆O₁₁: 815.3616 [M+H]⁺. Found: 815.3644. FAB-MS m/z (%): 815 (50, [M+H]⁺), ¹H-NMR (CDCl₃, major conformer, δ): 1.08 (3H, d, $J = 6.6$ Hz, Ala⁴-H_β), 1.28 (3H, d, $J = 6.9$ Hz, Ala¹-H_β), 2.62 (1H, dd, $J = 11.3, 2.8$ Hz, Tyr⁵-H_{βa}), 2.69–2.90 (4H, m, Asp²-H_β and Tyr⁶-H_β), 2.65 (3H, s, Tyr⁶-NMe), 3.05 (3H, s, Tyr³-NMe), 3.09 (3H, s, Tyr⁵-NMe), 3.16 (1H, dd, $J = 14.0, 10.4$ Hz, Tyr³-H_{βa}), 3.35 (1H, dd, $J = 14.0, 4.2$ Hz, Tyr³-H_{βb}), 3.59 (1H, dd, $J = 10.4, 4.2$ Hz, Tyr³-H_z), 3.65 (1H, t, $J = 11.3$ Hz, Tyr⁵-H_{βb}), 3.78 (3H, s, Tyr³-OMe), 3.92 (3H, s, Tyr⁶-OMe), 4.34 (1H, d, $J = 1.5$ Hz, Tyr⁶-H_{aa}), 4.47 (1H, dq, $J = 7.4, 6.9$ Hz, Ala¹-H_z), 4.57 (1H, dd, $J = 10.8, 4.5$ Hz, Tyr⁶-H_z), 4.69 (1H, dq, $J = 8.5, 6.6$ Hz, Ala⁴-H_z), 5.10 (1H, dd, $J = 13.7, 7.6$ Hz, Asp²-H_z), 5.38 (1H, dd, $J = 11.3, 2.8$ Hz, Tyr⁵-H_z), 6.53 (1H, d, $J = 7.4$ Hz, Ala¹-NH), 6.56 (1H, d, $J = 8.5$ Hz, Ala⁴-NH), 6.56 (1H, dd, $J = 8.5, 1.5$ Hz, Tyr⁶-H_{bb}), 6.79 (1H, d, $J = 8.5$ Hz, Tyr⁶-H_z), 6.84 (2H, d, $J = 8.4$ Hz, Tyr³-H_z), 6.86 (1H, dd, $J = 8.6, 2.4$ Hz, Tyr⁵-H_{aa}), 7.07 (2H, d, $J = 8.4$ Hz, Tyr³-H_z), 7.20 (1H, dd, $J = 8.4, 2.4$ Hz, Tyr⁵-H_{bb}), 7.24 (1H, dd, $J = 8.6, 2.1$ Hz, Tyr⁵-H_{aa}), 7.40 (1H, dd, $J = 8.4, 2.1$ Hz, Tyr⁵-H_{bb}), 7.80 (1H, d, $J = 7.6$ Hz, Asp²-NH).

b) Oxidation of 8 with NIS NIS (42.2 mg, 0.19 mmol) and K₂CO₃ (25.9 mg, 0.19 mmol) were added to a solution of **8** (59.8 mg, 0.075 mmol) in CH₃OH (2 ml) and the mixture was stirred at room temperature for 7 h. Then 5% Na₂S₂O₃ was added to the mixture, and the whole was concentrated *in vacuo*. The residue was dissolved in CH₂Cl₂. This solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12:2:1) to give [2-aspartic acid]-RA-VII methyl ester (**16**) (40.6 mg, 65%) as an amorphous powder. ¹H-NMR (CDCl₃, major conformer, δ): 1.12 (3H, d, $J = 6.7$ Hz, Ala⁴-H_β), 1.29 (3H, d, $J = 6.9$ Hz, Ala¹-H_β), 2.63 (1H, dd, $J = 11.3, 3.0$ Hz, Tyr⁵-H_{βa}), 2.67 (1H, dd, $J = 16.6, 6.0$ Hz, Asp²-H_{βa}), 2.67 (3H, s, Tyr⁶-NMe), 2.92 (1H, dd, $J = 16.5, 8.4$ Hz, Asp²-H_{βb}), 2.98–3.08 (2H, m, Tyr⁶-H_β), 3.10 (3H, s, Tyr³-NMe), 3.12 (3H, s, Tyr⁵-NMe), 3.24 (1H, dd, $J = 14.2, 10.5$ Hz, Tyr³-H_{βa}), 3.44 (1H, dd, $J = 14.2, 4.2$ Hz, Tyr³-H_{βb}), 3.59 (1H, dd, $J = 10.5, 4.2$ Hz, Tyr³-H_z), 3.67 (1H, t, $J = 11.3$ Hz, Tyr⁵-H_{βb}), 3.73 (3H, s, Asp²-OMe), 3.79 (3H, s, Tyr³-OMe), 3.93 (3H, s, Tyr⁶-OMe), 4.34 (1H, d, $J = 1.7$ Hz, Tyr⁶-H_{aa}), 4.38 (1H, t, $J = 6.9$ Hz, Ala¹-H_z), 4.56 (1H, dd, $J = 12.4, 3.8$ Hz, Tyr⁶-H_z), 4.71 (1H, dq, $J = 8.7, 6.7$ Hz, Ala⁴-H_z), 5.19 (1H, td, $J = 8.4, 6.0$ Hz, Asp²-H_z), 5.39 (1H, dd, $J = 11.3, 3.0$ Hz, Tyr⁵-H_z), 6.38 (1H, d, $J = 6.9$ Hz, Ala¹-NH), 6.58 (1H, dd, $J = 8.4, 1.7$ Hz, Tyr⁶-H_{bb}), 6.70 (1H, d, $J = 8.7$ Hz, Ala⁴-NH), 6.80 (2H, d, $J = 8.4$ Hz, Tyr⁶-H_z, Asp²-NH), 6.83 (2H, d, $J = 8.6$ Hz, Tyr³-H_z), 6.88 (1H, dd, $J = 8.6, 2.4$ Hz, Tyr⁵-H_{aa}), 7.07 (2H, d, $J = 8.6$ Hz, Tyr³-H_z), 7.21 (1H, dd, $J = 8.4, 2.4$ Hz, Tyr⁵-H_{bb}), 7.26 (1H, dd, $J = 8.6, 2.2$ Hz, Tyr⁵-H_{aa}), 7.41 (1H, dd, $J = 8.4, 2.2$ Hz, Tyr⁵-H_{bb}).

LiOH · H₂O (3.3 mg, 0.079 mmol) was added to a solution of **16** (40.5 mg, 0.048 mmol) in MeOH-H₂O (2 : 1, 2 ml) and the mixture was stirred at room temperature for 4 h, then acidified with 1 N HCl and concentrated *in vacuo*. The residue was dissolved in CH₂Cl₂. This solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12 : 2 : 1), followed by recrystallization from MeOH-isopropyl ether to give **15** (36.3 mg, 91%) as a colorless powder.

[2-Homoserine]-RA-VII (17) NaBH₄ (51.5 mg, 1.36 mmol) was added to a solution of **8** (272.0 mg, 0.34 mmol) in 1,4-dioxane (20 ml), and the mixture was stirred at room temperature for 3 h, then concentrated *in vacuo*. The residue was dissolved in CH₂Cl₂. This solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12 : 2 : 1), followed by recrystallization from MeOH-isopropyl ether to give **17** (246.6 mg, 90%) as a colorless powder, mp 261–262 °C, $[\alpha]_D^{20} -202.7^\circ$ ($c=0.09$, CHCl₃). IR ν (CHCl₃): 3401, 1669, 1636 cm⁻¹. UV λ_{\max} (EtOH) nm (log ϵ): 223 (4.55), 277 (3.64), 282 (3.60). High-resolution FAB-MS Calcd for C₄₂H₅₃N₆O₁₀: 801.3823 [M + H]⁺. Found: 801.3763. FAB-MS m/z (%): 801 (15, [M + H]⁺), 337 (100). ¹H-NMR (CDCl₃, major conformer, δ): 1.15 (3H, d, $J=6.6$ Hz, Ala⁴-H _{β), 1.31 (3H, d, $J=6.9$ Hz, Ala¹-H _{β), 1.93 (2H, m, Hse²-H _{β), 2.64 (1H, dd, $J=11.4$, 2.7 Hz, Tyr⁵-H _{β), 2.66 (3H, s, Tyr⁶-NMe), 2.93 (3H, s, Tyr³-NMe), 3.00 (1H, dd, $J=18.3$, 3.7 Hz, Tyr⁶-H _{β), 3.08 (1H, dd, $J=18.3$, 12.0 Hz, Tyr⁶-H _{β), 3.14 (3H, s, Tyr⁵-NMe), 3.23 (1H, dd, $J=14.2$, 10.9 Hz, Tyr³-H _{β), 3.42 (1H, dd, $J=14.2$, 4.3 Hz, Tyr³-H _{β), 3.59 (1H, dd, $J=10.9$, 4.3 Hz, Tyr³-H _{β}), 3.65 (1H, t, $J=11.4$ Hz, Tyr⁵-H _{β}), 3.70–3.79 (2H, m, Hse²-H _{γ}), 3.80 (3H, s, Tyr³-OMe), 3.90 (3H, s, Tyr⁶-OMe), 4.34 (1H, d, $J=2.0$ Hz, Tyr⁶-H _{α}), 4.41 (1H, dq, $J=7.2$, 6.9 Hz, Ala⁴-H _{α}), 4.52 (1H, dd, $J=12.0$, 3.7 Hz, Tyr⁶-H _{α}), 4.73 (1H, dq, $J=7.4$, 6.6 Hz, Ala⁴-H _{α}), 5.01 (1H, td, $J=7.7$, 7.0 Hz, Hse²-H _{α}), 5.38 (1H, dd, $J=11.4$, 2.7 Hz, Tyr⁵-H _{α}), 6.50 (1H, d, $J=7.2$ Hz, Ala¹-NH), 6.57 (1H, dd, $J=8.4$, 2.0 Hz, Tyr⁶-H _{β}), 6.73 (1H, d, $J=7.4$ Hz, Ala⁴-NH), 6.76 (1H, d, $J=8.4$ Hz, Tyr⁶-H _{β}), 6.81–6.85 (1H, m, Hse²-NH), 6.83 (2H, d, $J=8.6$ Hz, Tyr³-H _{α}), 6.88 (1H, dd, $J=8.4$, 2.4 Hz, Tyr⁵-H _{α}), 7.03 (2H, d, $J=8.6$ Hz, Tyr³-H _{α}), 7.21 (1H, dd, $J=8.4$, 2.4 Hz, Tyr⁵-H _{β}), 7.27 (1H, dd, $J=8.4$, 2.1 Hz, Tyr⁵-H _{α}), 7.43 (1H, dd, $J=8.4$, 2.1 Hz, Tyr⁵-H _{β}).}}}}}}}}

[2-Homoserine]-RA-VII Mesylate (18) MsCl (30 μ l, 0.34 mmol) was added dropwise to a solution of **17** (46.4 mg, 0.058 mmol), DMAP (21.2 mg, 0.17 mmol) and Et₃N (24 μ l, 0.17 mmol) in CH₂Cl₂ (5 ml) at -78 °C. The mixture was stirred at -78 °C for 2 h, then diluted with CH₂Cl₂, washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12 : 2 : 1) to give **18** (36.1 mg, 71%) as an amorphous powder. ¹H-NMR (CDCl₃, major conformer, δ): 1.08 (3H, d, $J=6.6$ Hz, Ala⁴-H _{β}), 1.28 (3H, d, $J=7.0$ Hz, Ala¹-H _{β}), 2.08–2.14 (2H, m, Hse²-H _{β}), 2.60–2.62 (1H, m, Tyr⁵-H _{β}), 2.64 (3H, s, Tyr⁶-NMe), 2.93 (3H, s, Tyr³-NMe), 2.96 (3H, s, Hse²-OMs), 2.98–3.07 (2H, m, Tyr⁶-H _{β}), 3.10 (3H, s, Tyr²-NMe), 3.26 (1H, dd, $J=14.1$, 11.0 Hz, Tyr³-H _{β}), 3.38 (1H, dd, $J=14.1$, 4.8 Hz, Tyr³-H _{β}), 3.61 (1H, dd, $J=11.0$, 4.8 Hz, Tyr³-H _{β}), 3.63 (1H, t, $J=11.2$ Hz, Tyr⁵-H _{β}), 3.76 (3H, s, Tyr³-OMe), 3.90 (3H, s, Tyr⁶-OMe), 4.14–4.20 (2H, m, Hse²-H _{γ}), 4.31 (1H, d, $J=1.9$ Hz, Tyr⁶-H _{α}), 4.40 (1H, m, Ala¹-H _{α}), 4.51 (1H, dd, $J=11.7$, 3.8 Hz, Tyr⁶-H _{α}), 4.70 (1H, dq, $J=7.3$, 6.6 Hz, Ala⁴-H _{α}), 4.95 (1H, dd, $J=11.3$, 3.2 Hz, Hse²-H _{α}), 5.36 (1H, dd, $J=11.2$, 3.2 Hz, Tyr⁵-H _{α}), 6.40 (1H, d, $J=7.0$ Hz, Hse²-NH), 6.54–6.57 (1H, m, Ala¹-NH), 6.55 (1H, dd, $J=8.3$, 1.9 Hz, Tyr⁶-H _{β}), 6.70 (1H, d, $J=7.3$ Hz, Ala⁴-NH), 6.77 (1H, d, $J=8.3$ Hz, Tyr⁶-H _{β}), 6.82 (2H, d, $J=8.5$ Hz, Tyr³-H _{α}), 6.84 (1H, dd, $J=8.4$, 2.1 Hz, Tyr⁵-H _{α}), 7.14 (1H, dd, $J=8.4$, 2.1 Hz, Tyr⁵-H _{β}), 7.23 (1H, dd, $J=8.4$, 2.1 Hz, Tyr⁵-H _{α}), 7.38 (1H, dd, $J=8.4$, 2.1 Hz, Tyr⁵-H _{β}).

[2-Vinyglycine]-RA-VII (19) A mixture of **18** (105.0 mg, 0.12 mmol), *o*-NO₂PhSeCN (54.5 mg, 0.24 mmol), NaBH₄ (9.1 mg, 0.24 mmol) and EtOH (10 ml) was stirred at room temperature for 24 h. The mixture was concentrated *in vacuo*, and the residue was dissolved in CH₂Cl₂. This solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12 : 2 : 1) to give the selenide. 35% H₂O₂ (2 ml) was added to the selenide dissolved in THF-EtOH (1 : 1, 20 ml), and the whole was stirred at room temperature for 12 h. Dimethyl sulfide was added to decompose excess H₂O₂, and the mixture was stirred at room temperature for 2 h. Then H₂O was added and the whole was concentrated

in vacuo. The residue was dissolved in CH₂Cl₂, and this solution was washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12 : 2 : 1), followed by recrystallization from MeOH-isopropyl ether to give **19** (16.3 mg, 17%) as a colorless powder, mp 261–262 °C, $[\alpha]_D^{20} -202.3^\circ$ ($c=0.12$, CHCl₃). IR ν (CHCl₃): 3400, 1675, 1636 cm⁻¹. UV λ_{\max} (EtOH) nm (log ϵ): 219 (4.48), 277 (3.61), 282 (3.56). High-resolution FAB-MS Calcd for C₄₂H₅₁N₆O₉: 783.3718 [M + H]⁺. Found: 783.3720. FAB-MS m/z (%): 783 (75, [M + H]⁺). ¹H-NMR (CDCl₃, major conformer, δ): 1.12 (3H, d, $J=6.6$ Hz, Ala⁴-H _{β}), 1.32 (3H, d, $J=6.9$ Hz, Ala¹-H _{β}), 2.60 (1H, dd, $J=11.9$, 3.9 Hz, Tyr⁵-H _{β}), 2.68 (3H, s, Tyr⁶-NMe), 2.87 (3H, s, Tyr³-NMe), 2.91–3.10 (2H, m, Tyr⁶-H _{β}), 3.12 (3H, s, Tyr⁵-NMe), 3.29 (1H, dd, $J=14.2$, 11.0 Hz, Tyr³-H _{β}), 3.40 (1H, dd, $J=14.2$, 4.4 Hz, Tyr³-H _{β}), 3.57 (1H, dd, $J=11.0$, 4.4 Hz, Tyr³-H _{β}), 3.66 (1H, t, $J=11.9$ Hz, Tyr⁵-H _{β}), 3.78 (3H, s, Tyr³-OMe), 3.93 (3H, s, Tyr⁶-OMe), 4.34 (1H, d, $J=1.8$ Hz, Tyr⁶-H _{α}), 4.42 (1H, qd, $J=6.9$, 6.8 Hz, Ala¹-H _{α}), 4.54 (1H, dd, $J=11.9$, 3.9 Hz, Tyr⁶-H _{α}), 4.74 (1H, dq, $J=7.5$, 6.6 Hz, Ala⁴-H _{α}), 5.33–5.42 (4H, m, Aa²-H _{α} , Aa²-H _{γ} and Tyr⁵-H _{α}), 5.86–5.95 (1H, m, Aa²-H _{β}), 6.46 (1H, d, $J=6.8$ Hz, Ala¹-NH), 6.58 (1H, dd, $J=8.4$, 1.8 Hz, Tyr⁶-H _{β}), 6.71 (1H, d, $J=7.5$ Hz, Ala⁴-NH), 6.76 (1H, d, $J=7.5$ Hz, Aa²-NH), 6.79 (1H, d, $J=8.4$ Hz, Tyr⁶-H _{β}), 6.80 (2H, d, $J=8.6$ Hz, Tyr³-H _{α}), 6.87 (1H, dd, $J=8.4$, 2.4 Hz, Tyr⁵-H _{α}), 7.02 (2H, d, $J=8.6$ Hz, Tyr³-H _{α}), 7.19 (1H, dd, $J=8.3$, 2.4 Hz, Tyr⁵-H _{β}), 7.26 (1H, dd, $J=8.4$, 2.1 Hz, Tyr⁵-H _{α}), 7.41 (1H, dd, $J=8.3$, 2.1 Hz, Tyr⁵-H _{β}).

[2-Methionine]-RA-VII (20) NaI (21.4 mg, 0.14 mmol) was added to a solution of **18** (50.0 mg, 0.057 mmol) in methyl ethyl ketone (3 ml), and the mixture was refluxed for 10 h, then concentrated *in vacuo* to leave a residue. A mixture of the residue, NaSCH₃ (19.9 mg, 0.28 mmol) and MeOH (4 ml) was stirred at room temperature for 0.5 h, then diluted with CH₂Cl₂, washed successively with H₂O, 1 N HCl, saturated NaHCO₃ and brine, and dried over MgSO₄. The solvent was evaporated off *in vacuo* to leave a residue, which was chromatographed on silica gel with CH₂Cl₂-AcOEt-MeOH (12 : 2 : 1), followed by recrystallization from MeOH-isopropyl ether to give **20** (43.0 mg, 91%) as a colorless powder, mp 204–205 °C, $[\alpha]_D^{20} -188.2^\circ$ ($c=0.13$, CHCl₃). IR ν (CHCl₃): 3407, 1676, 1636 cm⁻¹. UV λ_{\max} (EtOH) nm (log ϵ): 221 (4.47), 277 (3.59), 282 (3.34). High-resolution FAB-MS Calcd for C₄₃H₅₅N₆O₉S: 831.3751 [M + H]⁺. Found: 831.3754. FAB-MS m/z (%): 831 (70, [M + H]⁺). ¹H-NMR (CDCl₃, major conformer, δ): 1.12 (3H, d, $J=6.6$ Hz, Ala⁴-H _{β}), 1.30 (3H, d, $J=7.0$ Hz, Ala¹-H _{β}), 1.95–2.05 (2H, m, Met²-H _{β}), 2.08 (3H, s, Met²-SMe), 2.43–2.53 (2H, m, Met²-H _{α}), 2.64 (1H, dd, $J=11.3$, 3.1 Hz, Tyr⁵-H _{β}), 2.67 (3H, s, Tyr⁶-NMe), 2.92–2.98 (1H, m, Tyr⁶-H _{β}), 2.98 (3H, s, Tyr³-NMe), 3.01–3.10 (1H, m, Tyr⁶-H _{β}), 3.12 (3H, s, Tyr⁵-NMe), 3.30 (1H, dd, $J=14.3$, 11.0 Hz, Tyr³-H _{β}), 3.44 (1H, dd, $J=14.3$, 4.4 Hz, Tyr³-H _{β}), 3.63 (1H, dd, $J=11.0$, 4.4 Hz, Tyr³-H _{β}), 3.66 (1H, t, $J=11.3$ Hz, Tyr⁵-H _{β}), 3.78 (3H, s, Tyr³-OMe), 3.93 (3H, s, Tyr⁶-OMe), 4.34 (1H, d, $J=1.9$ Hz, Tyr⁶-H _{α}), 4.38 (1H, dd, $J=7.0$, 6.8 Hz, Ala¹-H _{α}), 4.54 (1H, dd, $J=12.3$, 4.2 Hz, Tyr⁶-H _{α}), 4.73 (1H, dq, $J=7.4$, 6.6 Hz, Ala⁴-H _{α}), 4.97 (1H, dd, $J=15.9$, 7.5 Hz, Met²-H _{α}), 5.39 (1H, dd, $J=11.3$, 3.1 Hz, Tyr⁵-H _{α}), 6.41 (1H, d, $J=6.8$ Hz, Ala¹-NH), 6.52 (1H, d, $J=8.7$ Hz, Met²-NH), 6.57 (1H, dd, $J=8.4$, 1.9 Hz, Tyr⁶-H _{β}), 6.71 (1H, d, $J=7.4$ Hz, Ala⁴-NH), 6.80 (1H, d, $J=8.4$ Hz, Tyr⁶-H _{β}), 6.83 (2H, d, $J=8.6$ Hz, Tyr³-H _{α}), 6.87 (1H, dd, $J=8.4$, 2.4 Hz, Tyr⁵-H _{α}), 7.06 (2H, d, $J=8.6$ Hz, Tyr³-H _{α}), 7.21 (1H, dd, $J=8.4$, 2.4 Hz, Tyr⁵-H _{β}), 7.26 (1H, dd, $J=8.4$, 2.2 Hz, Tyr⁵-H _{α}), 7.42 (1H, dd, $J=8.4$, 2.2 Hz, Tyr⁵-H _{β}).

Cell Survival by MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl Tetrazolium Bromide] Assay MTT colorimetric assay was performed in a 96-well plate.¹²⁾ The assay is dependent on the reduction of MTT by the mitochondrial dehydrogenase of viable cells to a blue formazan product which can be measured spectrophotometrically. Human KB oral epidermoid carcinoma cells (1 × 10⁴ cells/ml) or mouse P388 leukemia cells (2 × 10⁴ cells/ml) were inoculated in each well with 100 μ l of RPMI1640 medium (Gibco, Grand Island, NY) supplemented with 10% fetal calf serum (Flow Laboratories, U.K.), 100 units/ml of penicillin and 100 μ g/ml of streptomycin. After overnight incubation (37 °C, 5% CO₂), 100 μ l of sample solution was added to each well and the plates were incubated for 3 d (KB Cell) or 2 d (P388). Then 50 μ l of MTT (200 μ g/ml PBS) was added to each well and the plates were incubated for a further 4 h. The resulting formazan was dissolved in 150 μ l of DMSO. The plates was placed on a plate shaker for 5 min and read immediately at 540 nm. The IC₅₀ (μ g/ml) value was defined as that concentration of sample which caused 50% reduction of growth in sample-treated cells, with respect to the controls. The IC₅₀ was calculated by using the probit test.

In Vivo Antitumor Activity P388 murine leukemia cells (1 × 10⁶ cells)

were inoculated i.p. into female CDF₁ mice (6–7 weeks old, control: $n=16$; test: $n=8$) on day 0. Samples, suspended in 0.5% gum arabic-saline solution, were administered i.p. on days 1–5. The antitumor activity was estimated according to the NCI tumor panel screening method.¹³⁾

Acknowledgement We are grateful to Dr. Shiro Nakaike and Dr. Masaharu Tamai of Taisho Pharmaceutical Co., Ltd. for the biological evaluations.

References

- 1) Part III: H. Itokawa, K. Kondo, Y. Hitotsuyanagi, K. Takeya, *Heterocycles*, in press.
- 2) H. Itokawa, K. Takeya, K. Mihara, N. Mori, T. Hamanaka, T. Sonobe, Y. Iitaka, *Chem. Pharm. Bull.*, **31** 1424 (1983).
- 3) H. Itokawa, H. Morita, K. Takeya, N. Tomioka, A. Itai, Y. Iitaka, *Tetrahedron*, **47**, 7007 (1991).
- 4) H. Itokawa, T. Yamamiya, H. Morita, K. Takeya, *J. Chem. Soc., Perkin Trans. 1*, **1992**, 455.
- 5) P. A. Grieco, S. Gilman, M. Nishizawa, *J. Org. Chem.*, **41**, 1485 (1976).
- 6) H. Morita, K. Kondo, Y. Hitotsuyanagi, K. Takeya, H. Itokawa, N. Tomioka, A. Itai, Y. Iitaka, *Tetrahedron*, **47**, 2757 (1991).
- 7) W. P. Aue, E. Bartholdi, R. R. Ernst, *J. Chem. Phys.*, **64**, 2229 (1976).
- 8) A. Bax, S. Subramanian, *J. Magn. Reson.*, **67**, 565 (1986).
- 9) A. Bax, M. F. Summers, *J. Am. Chem. Soc.*, **108**, 2094 (1986).
- 10) G. Bodenhausen, H. Koger, R. R. Ernst, *J. Magn. Reson.*, **58**, 370 (1984).
- 11) M. Iqbal, P. Balam, *Biopolymers*, **21**, 1427 (1982).
- 12) J. Carmichael, W. G. DeGraff, A. F. Gazdar, J. D. Minna, J. B. Mitchell, *Cancer Res.*, **47**, 936 (1987).
- 13) J. M. Venditti, R. A. Wesley, J. Plowman, *Adv. Pharmacol. Chemother.*, **20**, 1 (1984).